Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries and Active Biotech have reported positive results for Phase III clinical trial which tested the efficacy of once-daily oral laquinimod in treating multiple sclerosis (MS).
Subscribe to our email newsletter
Laquinimod is an oral, once-daily CNS-active immunomodulator which can treat inflammation and neurodegeneration in MS.
The study, BRAVO demonstrated that laquinimod reduced annualized relapse rates (ARR), besides showing a reduction in the risk of disability progression.
The safety and tolerability profile of laquinimod was also favorable.